Efficacy and Safety of Amphotericin B and Azoles in the Treatment of Invasive Fungal Disease

A Retrospective Clinical Study on the Efficacy and Safety of Amphotericin B Compared With Azoles in the Treatment of Invasive Fungal Disease

Efficacy and safety of amphotericin B and azoles in the treatment of invasive fungal disease

The medical records, demographic characteristics and clinical data of patients with invasive fungal disease treated with amphotericin B or azoles were collected through the electronic medical record system of Sichuan Provincial People's Hospital from 2021 to 2024. To evaluate the efficacy and safety of these two types of drugs.

Inclusion Criteria:

• There is no age limit, gender is not limited
• Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for ≥ 7 days.

Exclusion Criteria:

• Patients with incomplete data or other factors affecting the clinical outcome judgement
• Patients who are judged by the investigator to be unsuitable to participate in this study.